A- A A+

EMCDDA. Older people and drugs: health and social responses 

This miniguide is one of a larger set, which together comprise Health and social responses to drug problems: a European guide. It provides an overview of the most important aspects to consider when planning or delivering health and social responses for older people using drugs, and reviews the availability and effectiveness of the responses. It also considers implications for policy and practice. (EMCDDA, Lissabon, 24.07.2023

https://www.emcdda.europa.eu/publications/mini-guides/older-people-and-drugs-health-and-social-responses_en

ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids. 

Weimer MB, Herring AA, Kawasaki SS, Meyer M, Kleykamp BA, Ramsey KS. J Addict Med. 2023 Jul 28. doi: 10.1097/ADM.0000000000001202. Epub ahead of print. PMID: 37505909.

https://journals.lww.com/journaladdictionmedicine/fulltext/9900/asam_clinical_considerations__buprenorphine.212.aspx

Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐Clinicians

Angela Di Paola, David Farabee, Sandra A. Springer

Psychiatric Research and Clinical Practice, Published Online:16 Aug 2023, doi.org/10.1176/appi.prcp.20230022

https://prcp.psychiatryonline.org/doi/10.1176/appi.prcp.20230022

USA. GUIDELINES FOR MANAGING SUBSTANCE WITHDRAWAL IN JAILS

A Tool for Local Government Officials, Jail Administrators, Correctional Officers, and Health Care Professionals

U.S. Department of Justice, Office of Justice Programs, Juni 2ß23

https://www.cossapresources.org/Content/Documents/JailResources/Guidelines_for_Managing_Substance_Withdrawal_in_Jails_6-6-23_508.pdf

USA. GUIDELINES FOR MANAGING SUBSTANCE WITHDRAWAL IN JAILS

A Tool for Local Government Officials, Jail Administrators, Correctional Officers, and Health Care Professionals

U.S. Department of Justice, Office of Justice Programs, Juni 2ß23

https://www.cossapresources.org/Content/Documents/JailResources/Guidelines_for_Managing_Substance_Withdrawal_in_Jails_6-6-23_508.pdf

Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations

Aili V Langford, Christine CW Lin, Lisa Bero, Fiona M Blyth, Jason Doctor, Simon Holliday, Yun‐Hee Jeon, Joanna Moullin, Bridin Murnion, Suzanne Nielsen, Rawa Osman, Jonathan Penm, Emily Reeve, Sharon Reid, Janet Wale, Carl R Schneider and Danijela Gnjidic

Med J Aust || doi: 10.5694/mja2.5200 Published online: 26 June 2023 

https://www.mja.com.au/journal/2023/219/2/clinical-practice-guideline-deprescribing-opioid-analgesics-summary

Operational definition of precipitated opioid withdrawal. 

Dunn KE, Bird HE, Bergeria CL, Ware OD, Strain EC, Huhn AS. 

Front Psychiatry. 2023 Apr 20;14:1141980. doi: 10.3389/fpsyt.2023.1141980. PMID: 37151972; PMCID: PMC10162012.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162012/

USA. Advisory: Evidence-Based, Whole Person Care of Pregnant People Who Have Opioid Use Disorder

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies. (Substance Abuse and Mental Health Services Administration (SAMHSA), USA, aufgerufen am 24.05.2023)

https://www.samhsa.gov/resource/ebp/advisory-whole-person-care-pregnant-people-opioid-use-disorder

Management of Infective Endocarditis in People Who Inject Drugs: A Scientific Statement From the American Heart Association. 

Baddour LM, Weimer MB, Wurcel AG, McElhinney DB, Marks LR, Fanucchi LC, Esquer Garrigos Z, Pettersson GB, DeSimone DC; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Peripheral Vascular Disease. 

Circulation. 2022 Oct 4;146(14):e187-e201. doi: 10.1161/CIR.0000000000001090. Epub 2022 Aug 31. PMID: 36043414.

https://www.ahajournals.org/doi/10.1161/CIR.0000000000001090

Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions. 

Bell AD, MacCallum C, Margolese S, Walsh Z, Wright P, Daeninck PJ, Mandarino E, Lacasse G, Kaur Deol J, de Freitas L, St Pierre M, Belle-Isle L, Gagnon M, Bevan S, Sanchez T, Arlt S, Monahan-Ellison M, O'Hara J, Boivin M, Costiniuk C; External Review Panel. Cannabis Cannabinoid Res. 2023 Mar 27. doi: 10.1089/can.2021.0156. Epub ahead of print. PMID: 36971587.

https://pubmed.ncbi.nlm.nih.gov/36971587/

VA/DoD Guideline Development Group. The Use of Opioids in the Management of Chronic Pain: Synopsis of the 2022 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. 

Friedhelm Sandbrink, Jennifer L. Murphy, Melanie Johansson, et al; 

Ann Intern Med. [Epub 14 February 2023]. doi:10.7326/M22-2917

https://www.acpjournals.org/doi/10.7326/M22-2917

USA. AATOD’s response to SAMHSA’s proposed regulations

(…) This letter provides an overview of what we consider to be most significant changes in the proposed rulemaking. We believe that these recommendations provide a thoughtful analysis of what needs to be reevaluated and changed. (AATOD - Association to the American Association for the Treatment of Opioid Dependence, USA, 10.02.2023)

https://files.constantcontact.com/55b56c59001/23c5ab69-8a75-4d46-9996-5ee4960f28fd.pdf

USA. Dr. Rahul Gupta Statement on Proposed Rule Changes to Expand Access to Treatment and Make It Easier to Get Care

WASHINGTON, D.C. – Today, Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), released a statement on the U.S. Department of Health and Human Services’ (HHS) proposed rule to expand access to treatment for opioid use disorder (OUD) by making permanent COVID-era policies that allow take home doses of methadone and the use of telehealth to access buprenorphine prescriptions. (The White House, USA, 13.12.2022)

https://www.whitehouse.gov/ondcp/briefing-room/2022/12/13/dr-rahul-gupta-statement-on-proposed-rule-changes-to-expand-access-to-treatment-and-make-it-easier-to-get-care/

Schweiz. Substitutionsgestützte Behandlungen bei Opioidabhängigkeit

Substitutionsgestützte Behandlungen richten sich an opioidabhängige Personen. Ein Substitutionsmittel wird im Rahmen einer therapeutischen Betreuung verschrieben, die somatische, psychiatrische, psychotherapeutische und sozialpädagogische Massnahmen umfasst. (Schweizerische Eidgenossenschaft, Bundesamt für Gesundheit, zuletzt aktualisiert 12.12.2022)

https://www.bag.admin.ch/bag/de/home/gesund-leben/sucht-und-gesundheit/suchtberatung-therapie/substitutionsgestuetzte-behandlung.html

National guidelines for medication-assisted treatment of opioid dependence

These guidelines for health professionals outline medications available for treating opioid dependence in Australia. They are intended for use by those not experienced in the treatment of alcohol and other drug problems. (Australian Government, Department of Health and Aged Care, April 2014)

https://www.health.gov.au/resources/publications/national-guidelines-for-medication-assisted-treatment-of-opioid-dependence

CDC Clinical Practice Guideline for Prescribing Opioids for Pain  United States, 2022.

Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. 

MMWR Recomm Rep 2022;71(No. RR-3):1–95. dx.doi.org/10.15585/mmwr.rr7103a1

https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm

USA. Medication-assisted Treatment (MAT): Statutes, Regulations, and Guidelines

Learn about the federal statutes, regulations, and guidelines that apply to medication-assisted treatment (MAT) for practitioners and opioid treatment programs (OTPs). (SAMHSA - Substance Abuse and Mental Health Services Administration, UA, zuletzt aufgerucfen am 04.11.2022)

https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines

EMCDDA. Health and social responses to drug problems: a European guide

Health and social responses to drug problems: a European guide examines some of the key public health challenges in the drugs field today and offers timely and practical advice to practitioners and policymakers for designing, targeting and implementing effective responses. The guide is composed of four sets of miniguides that look at responses to a range of drug problems in Europe. Framing the miniguides are two central resources: an action framework for developing responses and a set of strategies for successful implementation. Several spotlights frame issues cross-cutting the different components. (EMCDDA, Lissabon, Oktober 2022)

https://www.emcdda.europa.eu/publications/health-and-social-responses-a-european-guide_en

Schweiz. Berufsethischer Leitfaden für Heim- und Hausärzt:innen

Im Rahmen des Projektes «Ältere Menschen mit Abhängigkeit – Fachgerechte Betreuung und Behandlung» im Auftrag des Bundesamts für Gesundheit hat der Fachverband Sucht einen berufsethischen Leitfaden für Heim- und Hausärzt:innen erarbeitet. Die Inhalte resultieren aus einer Zusammenarbeit mit Fachpersonen aus der Suchtmedizin, der Hausarztmedizin, der Alterspsychiatrie und Pflegefachpersonen. (Fachverband Sucht, Schweiz, 2022)

https://fachverbandsucht.ch/de/news/berufsethischer-leitfaden-fur-heim-und-hausarztinnen

Opioid agonist treatment take-home doses ('carries'): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA? 

Russell C, Lange S, Kouyoumdjian F, Butler A, Ali F. 

Harm Reduct J. 2022 Aug 10;19(1):89. doi: 10.1186/s12954-022-00671-z. PMID: 35948961; PMCID: PMC9363267.

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-022-00671-z

Hospital Standards of Care for People with Substance Use Disorder. 

Englander H, Davis CS. 

N Engl J Med. 2022 Aug 20. doi: 10.1056/NEJMp2204687. Epub ahead of print. PMID: 35984354.

https://www.nejm.org/doi/full/10.1056/NEJMp2204687

Priority setting for Canadian Take-Home Naloxone best practice guideline development: an adapted online Delphi method. 

Ferguson M, Medley A, Rittenbach K, Brothers TD, Strike C, Ng J, Leece P, Elton-Marshall T, Ali F, Lorenzetti DL, Buxton JA. 

Harm Reduct J. 2022 Jul 2;19(1):71. doi: 10.1186/s12954-022-00650-4. PMID: 35780136; PMCID: PMC9250272.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250272/

Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. 

Calcaterra SL, Bottner R, Martin M, Englander H, Weinstein ZM, Weimer MB, Lambert E, Ronan MV, Huerta S, Zaman T, Ullal M, Peterkin AF, Torres-Lockhart K, Buresh M, O'Brien MT, Snyder H, Herzig SJ. 

J Hosp Med. 2022 Jul 26. doi: 10.1002/jhm.12908. Epub ahead of print. PMID: 35880821.

Abstract

https://pubmed.ncbi.nlm.nih.gov/35880821/

Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. 

Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO

https://www.who.int/publications/i/item/9789240052390

Schottland. MAT Website Launched

The newly launched website will host medication-assisted treatment (MAT) and MAT Standard information and resources for all stakeholders. SDF will host and curate the site. (SDF – Scottish Drugs Forum, UK, 18.07.2022)

https://www.matstandards.co.uk/

DEA. Narcotic Treatment Program Manual 

United States Department of Justice, Drug Enforcement Administration, Diversion Control Division

A Guide to DEA Narcotic Treatment Program Regulations, Revised 2022

DEA-DC-056, EO-DEA169, June 15, 2022

https://files.constantcontact.com/55b56c59001/14d39109-3557-4d66-b169-d481256152f4.pdf

 

Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. 

London: National Institute for Health and Care Excellence (NICE); 2022 Apr 20. PMID: 35609134.

https://www.ncbi.nlm.nih.gov/books/NBK580680/

Medicines associated with dependence or withdrawal symptoms: summary of NICE guideline 

Carville S, Lally M, Stannard C, Trewern L. 

BMJ 2022; 378 :o1454 doi:10.1136/bmj.o1454 

https://www.bmj.com/content/378/bmj.o1454

Schweiz. Neue Kapitel zu Opioid-Agonisten-Therapie auf alterundsucht.ch

06.07.22 / Die Wissensplattform «Alter und Sucht» richtet sich an Ärzt:innen, Fachpersonen aus der Suchthilfe und Pflege, die mit älteren Menschen zu tun haben, sowie ältere Menschen und deren Umfeld. Sie finden News, Praxisinstrumente, Konzepte, Fachpublikationen und Hinweise auf Veranstaltungen und Weiterbildungen.

Ab sofort sind auf der Webseite auch Themenkapitel zur Opioid-Agonisten-Therapie bei älteren Menschen für die Zielgruppen der Fachpersonen und Ärzteschaft verfügbar. Die Webinhalte wurden 2021 durch den Fachverband Sucht unter Einbezug von Expert:innen erarbeitet. Nebst aktuellen Informationen, bieten die Themenkapitel auch hilfreiche Links und Guidelines.

Die Versionen auf Französisch und Italienisch folgen im Laufe dieses Jahres. (Fachverband Sucht, Schweiz, 06.07.2022)

https://fachverbandsucht.ch/de/news/neue-kapitel-zur-opioid-agonisten-therapie-auf-alterundsuchtch

Clinical practice guideline on pharmacological and psychological management of adult patients with an anxiety disorder and comorbid substance use. 

Sáiz PA, Flórez G, Arrojo M, Bernardo M, González-Pinto A, Goikolea JM, Zorrilla I, Cunill R, Castells X, Becoña E, López A, Torrens M, Fonseca F, Tirado-Muñoz J, Arranz B, Garriga M, San L. 

Adicciones. 2022 Apr 1;34(2):157-167. English, Spanish. doi: 10.20882/adicciones.1548. PMID: 34171105.

https://adicciones.es/index.php/adicciones/article/view/1548